Format

Send to

Choose Destination
J Cancer. 2019 Jan 1;10(2):441-448. doi: 10.7150/jca.30041. eCollection 2019.

miR-1307-3p Stimulates Breast Cancer Development and Progression by Targeting SMYD4.

Author information

1
Department of Pathology, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Chuncheon 24253, Gangwon-Do, South Korea.
2
Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing 400042, China.
3
Department of Pharmacology, Scholl of Medicine, Kangwon National University, Chunchon 200-701, South Korea.
4
Department of Surgery, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Chuncheon, Gangwon-Do 24253, South Korea.
5
Department of Radiology, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Chuncheon, Gangwon-Do 24253, South Korea.
6
Department of Surgery, Kangdong Sacred Heart Hospital, College of Medicine, Hallym University, Seoul 134-776, South Korea.
7
Department of Surgery, Hallym Sacred Heart Hospital, College of Medicine, Hallym University, Anyang 14086, Gyeonggi-Do, South Korea.

Abstract

Recent studies show that dysregulated miRNAs play an important role in breast cancer initiation and progression. Here, we identified upregulated expression of miR-1307-3p in breast cancer tissues and that increased level of miR-1307-3p was closely correlated with lower survival rate in breast cancer patients. Consistent with clinical data, our in vitro data show that expression level of miR-1307-3p was significantly increased in breast cancer cell lines compared to human mammary epithelial cell line MCF10A. Overexpression of miR-1307-3p in MCF10A stimulated cell proliferation and caused their growth in soft agar and tumor formation in nude mice. In contrast, inhibition of miR-1307-3p suppressed breast cancer cell proliferation and their growth in soft agar and inhibited tumor formation in nude mice. Further, we identified that miR-1307-3p plays its oncogenic role through targeting SET and MYND domain-containing 4 (SMYD4) expression in breast cancer. Taken together, our findings suggest that miR-1307-3p is a oncogenic miRNA that significantly contributes to breast cancer development and progression, and inhibition of miR-1307-3p may be a novel strategy for inhibits breast cancer initiation and progression.

KEYWORDS:

SMYD4; breast cancer; miR-1307-3p; tumorigenesis

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Supplemental Content

Full text links

Icon for Ivyspring International Publisher Icon for PubMed Central
Loading ...
Support Center